NDAORALCAPSULE
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
SODIUM IODIDE I 131 (sodium iodide i-131) by CIS Pharma is sodium-iodide symporter (nis) protein, in thyroid follicular cells. Approved for hyperthyroidism, selected cases of carcinoma of the thyroid. First approved in 1976.
Drug data last refreshed 14h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Sodium Iodide I-131 is an oral radioactive iodine capsule used to treat hyperthyroidism and select thyroid carcinomas. The drug works by concentrating in thyroid follicular cells via the sodium-iodide symporter, where beta emission from I-131 destroys thyroid tissue. This mechanism provides targeted radiotherapeutic effect for both benign and malignant thyroid conditions.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating team transition toward generic defense and cycle management rather than growth initiatives.
Mechanism of Action
sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I) which in turn iodinates tyrosine residues of thyroglobulin (tri…
Indications (2)
Worked on SODIUM IODIDE I 131 at CIS Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.